FULC (Fulcrum Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by FULC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-20 | TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | Buy | — | — |
| 2026-07-15 | TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | Buy | — | — |
| 2026-07-02 | Kate Haviland | Director | A | — | — |
| 2026-07-02 | JAMES A GERAGHTY | Director | A | — | — |
| 2026-07-02 | Colin Hill | Director | A | — | — |
| 2026-07-02 | Alan Ezekowitz | Director | A | — | — |
| 2026-07-02 | Robert J Gould | Director | A | — | — |
| 2026-07-02 | Rachel K. King | Director | A | — | — |
| 2026-07-02 | Katina Dorton | Director | A | — | — |
| 2026-07-02 | Sonja Banks | Director | A | — | — |
| 2026-05-01 | Joshua Lehrer-Graiwer | Director | A | — | — |
| 2026-02-04 | Robert J Gould | Director | Sell | — | — |
| 2026-02-04 | Curtis Gale Oltmans | Chief Legal Officer | A | — | — |
| 2026-02-04 | Alex Sapir | See Remarks | A | — | — |
| 2026-02-04 | Greg Tourangeau | Principal Accounting Officer | A | — | — |
| 2026-02-04 | Alan A Musso | Chief Financial Officer | A | — | — |
| 2026-02-04 | Robert J Gould | Director | Sell | — | — |
| 2026-01-06 | Robert J Gould | Director | Sell | — | — |
| 2025-12-17 | Curtis Gale Oltmans | Chief Legal Officer | Sell | — | — |
| 2025-12-10 | Rajeev M. Shah | 10%+ Owner | Sell | — | — |
| 2025-11-21 | Robert J Gould | Director | Sell | — | — |
| 2025-06-30 | Kate Haviland | Director | A | — | — |
| 2025-06-30 | Alan Ezekowitz | Director | A | — | — |
| 2025-06-30 | Robert J Gould | Director | A | — | — |
| 2025-06-30 | Katina Dorton | Director | A | — | — |
| 2025-06-30 | Rachel K. King | Director | A | — | — |
| 2025-06-30 | JAMES A GERAGHTY | Director | A | — | — |
| 2025-06-30 | Colin Hill | Director | A | — | — |
| 2025-06-30 | Sonja Banks | Director | A | — | — |
| 2025-05-09 | Greg Tourangeau | Principal Accounting Officer | Sell | — | — |
| 2025-01-28 | Curtis Gale Oltmans | Chief Legal Officer | A | — | — |
| 2025-01-28 | Alan A Musso | Chief Financial Officer | A | — | — |
| 2025-01-28 | Greg Tourangeau | Principal Accounting Officer | A | — | — |
| 2025-01-28 | Alex Sapir | See Remarks | A | — | — |
| 2024-11-14 | Rachel K. King | Director | A | — | — |
| 2024-08-23 | RA Capital Healthcare Fund LP | 10%+ Owner | J | — | — |
| 2024-07-08 | Alex Sapir | See Remarks | M | — | — |
| 2024-06-18 | Katina Dorton | Director | A | — | — |
| 2024-06-18 | JAMES A GERAGHTY | Director | A | — | — |
| 2024-06-18 | Kate Haviland | Director | A | — | — |
| 2024-06-18 | Robert J Gould | Director | A | — | — |
| 2024-06-18 | Colin Hill | Director | A | — | — |
| 2024-06-18 | Alan Ezekowitz | Director | A | — | — |
| 2024-06-18 | Sonja Banks | Director | A | — | — |
| 2024-06-18 | James J. Collins | Director | A | — | — |
| 2024-05-09 | Greg Tourangeau | Principal Accounting Officer | Sell | — | — |
| 2024-03-20 | Patrick Taylor Horn | Chief Medical Officer | A | — | — |
| 2024-03-08 | Greg Tourangeau | Vice President, Finance | Sell | — | — |
| 2024-03-05 | Alex Sapir | See Remarks | Buy | — | — |
| 2024-01-30 | Curtis Gale Oltmans | Chief Legal Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 9,686,628 | — |
| — | 10%+ Owner | 8,852,079 | — |
| — | 10%+ Owner | 7,824,600 | — |
| — | 10%+ Owner | 7,305,356 | — |
| — | 10%+ Owner | 7,030,000 | — |
| — | 10%+ Owner | 5,962,202 | — |
| — | 10%+ Owner | 4,305,356 | — |
| — | 10%+ Owner | 3,109,704 | — |
| — | 10%+ Owner | 2,427,374 | — |
| — | 10%+ Owner | 2,343,154 | — |
| — | 10%+ Owner | 1,785,714 | — |
| — | Director | 469,864 | — |
| — | 10%+ Owner | 464,285 | — |
| — | 10%+ Owner | 464,285 | — |
| — | 10%+ Owner | 464,285 | — |
| — | 10%+ Owner | 441,071 | — |
| — | See Remarks | 193,360 | — |
| — | Chief Scientific Officer | 133,438 | — |
| — | Director | 90,714 | — |
| — | Director | 84,223 | — |
| — | SVP Clinical Development | 65,714 | — |
| — | VP Finance & Accounting | 22,512 | — |
| — | Principal Accounting Officer | 14,062 | — |
| — | Chief Legal Officer | 10,252 | — |
| — | Chief Medical Officer | 1,100 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FULC quote page; the site-wide leaderboard is on the insider transactions hub.